Elena Tagliabue 1 , Sara Raimondi 1 , Sara Gandini 2 Show Affiliations »
Abstract
BACKGROUND: Epidemiologic evidence supported a role for vitamin D and vitamin D receptor (VDR) polymorphisms in cancer risk. Beyond VDR, the biologic effects of vitamin D are mediated by the vitamin D-binding protein (DBP), a key protein in vitamin D metabolism. Furthermore, the gene encoding the DBP (GC, group-specific component) has an important role in the vitamin D pathway. Several studies investigated DBP serologic levels and GC polymorphisms in association with cancer risk with controversial results. Thus, we carried out a meta-analysis to investigate these associations. METHODS: We included 28 independent studies concerning the following tumors: basal cell carcinoma, bladder, breast, colon-rectum, endometrium, liver, esophagus, stomach, melanoma, pancreas, prostate, and kidney. Through random-effect models, we calculated the summary odds ratios (SOR) for serum DBP and the GC polymorphisms rs2282679, rs12512631, rs7041, rs4588, rs17467825, rs1155563, and rs1352844. RESULTS: We found a borderline decrease in cancer risk for subjects with high compared with low levels of DBP [SOR, 0.75; 95% confidence interval (CI), 0.56-1.00]. Dose-response meta-analysis indicates a nonsignificant decrease risk for an increase of 1,000 nmol/L of DBP (SOR, 0.96; 95% CI, 0.91-1.01). We found no significant alterations in cancer risk for subjects carrying any of the studied GC polymorphisms compared with wild-type subjects both in the main analysis and in analyses stratified by cancer type and ethnicity. CONCLUSIONS: We found trends toward significance, suggesting a role of DBP in cancer etiology, which should be confirmed in further studies. IMPACT: To our knowledge, this is the first study to investigate GC polymorphisms and DBP serologic levels in association with any type of cancer. ©2015 American Association for Cancer Research.
BACKGROUND: Epidemiologic evidence supported a role for vitamin D and vitamin D receptor (VDR ) polymorphisms in cancer risk. Beyond VDR , the biologic effects of vitamin D are mediated by the vitamin D-binding protein (DBP ), a key protein in vitamin D metabolism. Furthermore, the gene encoding the DBP (GC, group-specific component) has an important role in the vitamin D pathway. Several studies investigated DBP serologic levels and GC polymorphisms in association with cancer risk with controversial results. Thus, we carried out a meta-analysis to investigate these associations. METHODS: We included 28 independent studies concerning the following tumors : basal cell carcinoma , bladder, breast, colon-rectum , endometrium, liver, esophagus, stomach, melanoma , pancreas , prostate, and kidney. Through random-effect models, we calculated the summary odds ratios (SOR) for serum DBP and the GC polymorphisms rs2282679 , rs12512631 , rs7041 , rs4588 , rs17467825 , rs1155563 , and rs1352844 . RESULTS: We found a borderline decrease in cancer risk for subjects with high compared with low levels of DBP [SOR, 0.75; 95% confidence interval (CI), 0.56-1.00]. Dose-response meta-analysis indicates a nonsignificant decrease risk for an increase of 1,000 nmol/L of DBP (SOR, 0.96; 95% CI, 0.91-1.01). We found no significant alterations in cancer risk for subjects carrying any of the studied GC polymorphisms compared with wild-type subjects both in the main analysis and in analyses stratified by cancer type and ethnicity. CONCLUSIONS: We found trends toward significance, suggesting a role of DBP in cancer etiology, which should be confirmed in further studies. IMPACT: To our knowledge, this is the first study to investigate GC polymorphisms and DBP serologic levels in association with any type of cancer . ©2015 American Association for Cancer Research.
Entities: Chemical
Disease
Gene
Mutation
Mesh： See more »
Substances： See more »
Year: 2015
PMID： 26364161 DOI： 10.1158/1055-9965.EPI-15-0262
Source DB: PubMed Journal: Cancer Epidemiol Biomarkers Prev ISSN： 1055-9965 Impact factor: 4.254